title: [Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine].
abstract: Prophylaxis against bone fracture with osteoporosis therapy is of significant importance not only for preserving patients' activities of daily living (ADL) and quality of life(QOL), but also for saving and making effective use of social overhead capital. The author has treated patients with osteoporosis with risedronate, a bisphosphonate which has produced evidence of its clear efficacy in prophylaxis against bone fracture. The study has shown that the use of risedronate normalizes abnormal bone metabolism in a short time, which could not be corrected with active vitamin D3 preparations. Although bisphosphonates are effective in treatment of osteoporosis, a strict instruction to patients on the dosage often results in their inadequate compliance with the therapy. Thus, an instruction on the dosage more flexible about the timing of taking the drug was given, and then higher clinical benefit was obtained. By giving patients sufficient information on the importance of osteoporosis therapy and instructions on the dosage with a certain level of flexibility, osteoporosis therapy which brings out the greater potential of risedronate can be performed.
authors.affiliation: Ijiri Orthopaedic Clinic.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Ijiri
mesh_terms: D000328:Adult; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D010349:Patient Compliance; D010353:Patient Education as Topic; D000068296:Risedronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid